- Pharmacology
- Allergy, Immunology, and ENT
- Cardiology
- Emergency Medicine
- Endocrinology
- Adolescent Medicine
- Gastroenterology
- Infectious Diseases
- Neurology
- OB/GYN
- Practice Improvement
- Gynecology
- Respiratory
- Dermatology
- Mental, Behavioral and Development Health
- Oncology
- Rheumatology
- Sexual Health
- Pain
Fluoroquinolones no longer recommended for STDs
After analyzing preliminary data from 2006, indicating that fluoroquinolone-resistant gonorrhea is now widespread across the nation, the Centers for Disease Control and Prevention (CDC) is no longer recommending that the fluoroquinolone class of antibiotics be used to treat gonorrhea in the US.
After analyzing preliminary data from 2006, indicating that fluoroquinolone-resistant gonorrhea is now widespread across the nation, the Centers for Disease Control and Prevention (CDC) is no longer recommending that the fluoroquinolone class of antibiotics be used to treat gonorrhea in the US.
Data from the CDC's Gonoccocal Isolate Surveillance project (GISP) in 26 US cities show that cases of fluoroquinolone-resistant gonorrhea have increased in the first half of 2006 among heterosexual men (6.7% from 0.6% in 2001) and homosexual men (38%). With the loss of fluoroquinolone class, recommended gonorrhea treatments are limited to the cephalosporin class of antibiotics. (MMWR Morbid Mortal Wkly Rep 2007;56:332)
